Bausch Health Companies Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Michael Goettler resigned from Bausch Health's Board of Directors effective June 30, 2026, due to his appointment as President and CEO of Knoa Pharma LLC. The resignation was not due to any disagreement with the company. No financial terms, compensation details, or Goettler's prior role details are disclosed in the filing.
Why this rating
Routine board departure. One director loss immaterial to $2B company. No financial impact disclosed. Standard governance event.
Extracted items
- 5.02 exec change
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.